239 related articles for article (PubMed ID: 11840884)
1. Lipid lowering agents. How important are they in secondary prevention of coronary heart disease?
Colquhoun DM
Aust Fam Physician; 2002 Jan; 31(1):25-6, 29-30. PubMed ID: 11840884
[TBL] [Abstract][Full Text] [Related]
2. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
[TBL] [Abstract][Full Text] [Related]
3. Statins for primary and secondary prevention of coronary heart disease. A scientific review.
Carneiro AV; Costa J; Borges M
Rev Port Cardiol; 2004 Jan; 23(1):95-122. PubMed ID: 15058150
[TBL] [Abstract][Full Text] [Related]
4. Economic benefits of aggressive lipid lowering: a managed care perspective.
McKenney JM; Kinosian B
Am J Manag Care; 1998 Jan; 4(1):65-74. PubMed ID: 10179907
[TBL] [Abstract][Full Text] [Related]
5. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
[TBL] [Abstract][Full Text] [Related]
6. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
7. [The role of cholesterol-lowering drugs in prevention of coronary heart disease].
Skałuba Z; Undas R
Przegl Lek; 1998; 55(7-8):382-7. PubMed ID: 10021881
[TBL] [Abstract][Full Text] [Related]
8. What do the statins tell us?
LaRosa JC
Am Heart J; 2002 Dec; 144(6 Suppl):S21-6. PubMed ID: 12486412
[TBL] [Abstract][Full Text] [Related]
9. Unstable angina--a definitive role for statins in secondary prevention.
Colquhoun D
Int J Clin Pract; 2000; 54(6):383-9. PubMed ID: 11092112
[TBL] [Abstract][Full Text] [Related]
10. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease.
Marchioli R; Marfisi RM; Carinci F; Tognoni G
Arch Intern Med; 1996 Jun; 156(11):1158-72. PubMed ID: 8639010
[TBL] [Abstract][Full Text] [Related]
12. Primary prevention: a simple, effective means of risk reduction.
Gaw A
Int J Clin Pract Suppl; 2002 Jul; (130):6-12. PubMed ID: 12296608
[TBL] [Abstract][Full Text] [Related]
13. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol and coronary events. The current thinking.
Jones PH
Postgrad Med; 2003 Apr; 113(4 Suppl):5-14. PubMed ID: 19667618
[TBL] [Abstract][Full Text] [Related]
16. Prevention of mortality from coronary heart disease with pravastatin.
Tonkin AM; Ryan EW
Biomed Pharmacother; 1999 Oct; 53(9):405-8. PubMed ID: 10554675
[TBL] [Abstract][Full Text] [Related]
17. Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization.
Cooke CE; Hammerash WJ
Clin Ther; 2006 Apr; 28(4):591-9. PubMed ID: 16750470
[TBL] [Abstract][Full Text] [Related]
18. Clinical inquiries. Which patients benefit from lowering LDL to <100 mg/dL?
Evensen A; Elliott M; Hooper-Lane C
J Fam Pract; 2010 Dec; 59(12):706-8. PubMed ID: 21135927
[TBL] [Abstract][Full Text] [Related]
19. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events.
Ridker PM; Shih J; Cook TJ; Clearfield M; Downs JR; Pradhan AD; Weis SE; Gotto AM;
Circulation; 2002 Apr; 105(15):1776-9. PubMed ID: 11956118
[TBL] [Abstract][Full Text] [Related]
20. Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management.
Leitersdorf E
Int J Clin Pract; 2002 Mar; 56(2):116-9. PubMed ID: 11926698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
